• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>GlaxoSmithKline

GlaxoSmithKline

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. GlaxoSmithKline Announces Positive Results for Triple-Therapy Inhaler

    GlaxoSmithKline Announces Positive Results for Triple-Therapy Inhaler

  2. GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations

    GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations

  3. Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

    Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

  4. Moderna Announces Pipeline and Corporate Update

    Moderna Announces Pipeline and Corporate Update

  5. FTSE 100 stays under pressure from a strengthening pound

    FTSE 100 stays under pressure from a strengthening pound

  6. UPDATE: FTSE 100 ends lower, with miners leading the way down

    UPDATE: FTSE 100 ends lower, with miners leading the way down

12345

©2017 Morningstar Advisor. All right reserved.